2-氨基-2-乙基己酸乙酯 | 152802-65-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-氨基-2-乙基己酸乙酯
• 英文名称: (+/-)-ethyl 2-amino-2-ethylhexanoate
• 英文别名: 2-amino-2-ethylhexanoic acid ethyl ester；Ethyl 2-amino-2-ethylhexanoate
• CAS: 152802-65-8
• 化学式: C₁₀H₂₁NO₂
• 分子量: 187.282
• InChiKey: PUFPKUWTAGCFPT-UHFFFAOYSA-N

物化性质

• 沸点：
  232.8±13.0 °C(Predicted)
• 密度：
  0.932±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2922499990

反应信息

• 作为反应物：
  描述：

  2-氨基-2-乙基己酸乙酯 在 porcine liver esterase 、 sodium hydroxide 、 sodium tetrahydroborate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 phosphate buffer 、 乙醇 、 水 、 乙腈 为溶剂， 反应 242.5h， 生成 ethyl (S)-2-butyl-2-ethylglycyl-(S)-2-butyl-2-ethylglycyl-(S)-2-butyl-2-ethylglycinyl-(S)-2-butyl-2-ethylglycinyl-(S)-2-butyl-2-ethylglycinate
  参考文献：
  名称：

  The First Fully Planar C ₅ ‐Conformation of Homooligopeptides Prepared from a Chiral α ‐Ethylated α , α ‐Disubstituted Amino Acid: ( S )‐Butylethylglycine (=(2 S )‐2‐Amino‐2‐ethylhexanoic Acid)

  摘要：

  An optically active alpha -ethylated alpha,alpha -disubstituted amino acid, (S)-butylethylglycine (= (2S)-2-amino-2-ethylhexanoic acid; (S)-Beg; (S)-2),was prepared starring from butyl ethyl ketone (1) by the Strecker method and enzymatic kinetic resolution of the racemic amino acid. Homooligopeptides containing (S)-Beg (up to hexapeptide) were synthesized by conventional solution methods. An ethyl cater was used for the protection at the C-terminus, and a trifluoroacetyl group was used for the N-terminus of the peptides. Thr structures of tri- and tetrapeptides 5 and 6 in the solid state were solved by X-ray crystallographic analysis, and were shown to have a bent planar C-conformation (tripeptide) and a fully planar C-5-conformation (tetrapeptide) (see Figs. I and 2, resp.). The IR and H-1-NMR spectra of hexapeptide 8 revealed that the dominant conformation in CDCl3, solution was also a fully planar C-5-conformation, These results show for the first time that the preferred conformation of homopeptides containing a chiral alpha -ethylated alpha,alpha -disubstituted amino acid is a planar C-5-conformation.

  DOI：

  10.1002/1522-2675(20001004)83:10<2823::aid-hlca2823>3.0.co;2-#
• 作为产物：
  描述：

  3-庚酮 在 盐酸 、 硫酸 、 氯化铵 作用下， 以 乙醇 、 水 为溶剂， 反应 72.0h， 生成 2-氨基-2-乙基己酸乙酯
  参考文献：
  名称：

  The First Fully Planar C ₅ ‐Conformation of Homooligopeptides Prepared from a Chiral α ‐Ethylated α , α ‐Disubstituted Amino Acid: ( S )‐Butylethylglycine (=(2 S )‐2‐Amino‐2‐ethylhexanoic Acid)

  摘要：

  An optically active alpha -ethylated alpha,alpha -disubstituted amino acid, (S)-butylethylglycine (= (2S)-2-amino-2-ethylhexanoic acid; (S)-Beg; (S)-2),was prepared starring from butyl ethyl ketone (1) by the Strecker method and enzymatic kinetic resolution of the racemic amino acid. Homooligopeptides containing (S)-Beg (up to hexapeptide) were synthesized by conventional solution methods. An ethyl cater was used for the protection at the C-terminus, and a trifluoroacetyl group was used for the N-terminus of the peptides. Thr structures of tri- and tetrapeptides 5 and 6 in the solid state were solved by X-ray crystallographic analysis, and were shown to have a bent planar C-conformation (tripeptide) and a fully planar C-5-conformation (tetrapeptide) (see Figs. I and 2, resp.). The IR and H-1-NMR spectra of hexapeptide 8 revealed that the dominant conformation in CDCl3, solution was also a fully planar C-5-conformation, These results show for the first time that the preferred conformation of homopeptides containing a chiral alpha -ethylated alpha,alpha -disubstituted amino acid is a planar C-5-conformation.

  DOI：

  10.1002/1522-2675(20001004)83:10<2823::aid-hlca2823>3.0.co;2-#

文献信息

• [EN] COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PYRIDOPYRIMIDINE DERIVATIVES<br/>[FR] ASSOCIATION DE VACCINS CONTRE LE VIRUS DE L'HÉPATITE B (VHB) ET DE DÉRIVÉS DE PYRIDOPYRIMIDINE
  申请人：JANSSEN SCIENCES IRELAND UNLIMITED CO

  公开号：WO2020255038A1

  公开（公告）日：2020-12-24

  Therapeutic combinations of hepatitis B virus (HBV) vaccines and a pyridopyrimidine derivative are described. Methods of inducing an immune response against HBV or treating an HBV-induced disease, particularly in individuals having chronic HBV infection, using the disclosed therapeutic combinations are also described. The invention provides therapeutic combinations or compositions and methods for inducing an immune response against hepatitis B viruses (HBV) infection.

  本发明描述了乙型肝炎病毒（HBV）疫苗和吡啶吡嘧啶衍生物的治疗组合。还描述了利用所述治疗组合诱导免疫应答对抗HBV或治疗HBV引起的疾病的方法，特别是在患有慢性HBV感染的个体中。该发明提供了用于诱导免疫应答对抗乙型肝炎病毒（HBV）感染的治疗组合或组成物和方法。
• TOLL LIKE RECEPTOR MODULATOR COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：US20160289229A1

  公开（公告）日：2016-10-06

  The present disclosure relates generally to toll like receptor modulator compounds, such as diamino pyrido[3,2 D]pyrimidine compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR-8), and methods of making and using them.

  本公开涉及调节类似受体调节剂化合物，例如二氨基吡啶并[3,2 D]嘧啶化合物和药物组合物，其中调节类似受体（例如TLR-8），以及制备和使用它们的方法。
• BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS
  申请人：Albireo AB

  公开号：US20190367467A1

  公开（公告）日：2019-12-05

  The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.

  本发明涉及式(I)的1,5-苯并噻嗪和1,2,5-苯并噻二嗪衍生物。这些化合物是胆酸调节剂，具有顶端钠依赖性胆酸转运蛋白（ASBT）和/或肝脏胆酸转运（LBAT）抑制活性。本发明还涉及包含这些化合物的药物组合物，以及这些化合物在治疗心血管疾病、脂肪酸代谢和葡萄糖利用障碍、胃肠疾病和肝脏疾病中的用途。
• Hypolipidemic 1,4-benzothiazepine derivative
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP1203769A1

  公开（公告）日：2002-05-08

  The invention is concerned with a novel hypolipidemic compound, which is of (3R,5R)-3-Butyl-3-ethyl-2,3,4,5-tetrahydro-7-methoxy-5-phenyl-1,4-benzothiazepin-8-ol 1,1-dioxide; or a salt, solvate, or physiologically functional derivative thereof, with processes for its preparation, pharmaceutical compositions containing it and with its use in medicine, particularly in the prophylaxis and treatment of hyperlipidemic conditions, such as athersclerosis.

  这项发明涉及一种新型降脂化合物，即(3R,5R)-3-丁基-3-乙基-2,3,4,5-四氢-7-甲氧基-5-苯基-1,4-苯并噻吩-8-醇-1,1-二氧化物；或其盐、溶剂合物或生理功能衍生物，以及其制备方法、含有它的药物组合物，以及在医学中的应用，特别是在预防和治疗高脂血症等高脂血症状况中的使用。
• Enzymatic- and Iridium-Catalyzed Asymmetric Synthesis of a Benzothiazepinylphosphonate Bile Acid Transporter Inhibitor
  作者：David J. Cowan、Jon L. Collins、Mark B. Mitchell、John A. Ray、Peter W. Sutton、Amy A. Sarjeant、Eric E. Boros

  DOI：10.1021/jo402311e

  日期：2013.12.20

  A synthesis of the benzothiazepine phosphonic acid 3, employing both enzymatic and transition metal catalysis, is described. The quaternary chiral center of 3 was obtained by resolution of ethyl (2-ethyl)norleucinate (4) with porcine liver esterase (PLE) immobilized on Sepabeads. The resulting (R)-amino acid (5) was converted in two steps to aminosulfate 7, which was used for construction of the benzothiazepine

  描述了同时使用酶催化和过渡金属催化的苯并噻氮平膦酸3的合成。通过用固定在Sepabeads上的猪肝酯酶（PLE）拆分（2-乙基）去甲亮氨酸乙酯（4），可以得到3的四级手性中心。分两步将所得的（R）-氨基酸（5）转化为氨基硫酸盐7，该氨基硫酸盐7用于构造苯并噻氮平环。由三甲基氢醌11分四个步骤制备的苯甲酮15使磷（Arbuzov化学）和硫（Pd（0）催化的硫醇偶联）的顺序引入成为了硫醇中间体18。用氨基硫酸盐7进行18的S-烷基化，然后进行环脱水，得到二氢苯并硫氮杂pine 20。铱在[Ir（COD）2 BArF]（26）和Taniaphos配体P的配合物中催化的20的不对称氢化反应提供了（3 R，5 R）-四氢苯并硫氮杂卓30。将30氧化为砜31并进行膦酸酯水解，完成12个步骤中3的合成，总产率为13％。